In addition to enhanced absorption, our formulation is held to the highest standards of purity
The STEP 1 trial (Wilding et al., N Engl J Med, 2021) documented nausea in 44.2% of participants at the 2.4 mg dose versus 17.4% on placebo
doi: 10.3389/fcvm.2026.1813873 Received 19 February 2026 Revised 04 April 2026 Accepted 07 April 2026 Published 14 May 2026 Volume 13 - 2026 Edited by Emiel Van Der Vorst, University Hospital RWTH Aachen, Germany Reviewed by Monica de Gaetano, University College Dublin, Ireland Updates Copyright 2026 Al-Taweel and Malki
Always consult with a healthcare provider for a complete list of interactions
CAS, Canadian Anesthesiologists Society
ICD-10 documentation for comorbid conditions follows the same principle: every secondary code must have a clear, contemporaneous clinical record to support it